T&L Co

T&L Co ROIC

The Return on Invested Capital (ROIC) of T&L Co (340570.KQ) as of Oct 30, 2026 is 18.93 %. In the previous year, Return on Invested Capital (ROIC) was 27.00 % — a change of -29.89% (lower).

ROIC

18.93 %

YoY

-29.89%

Last updated:

Return on Invested Capital (ROIC) of T&L Co is 2025 18.93 % . Return on Invested Capital (ROIC) of T&L Co was 2024 27.00 % . It decreases by -29.89% lower compared to the previous year.

The T&L Co ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
14.74 KRW
Jan 1, 2019
19.92 KRW
Jan 1, 2020
13.94 KRW
Jan 1, 2021
21.68 KRW
Jan 1, 2022
19.89 KRW
Jan 1, 2023
21.16 KRW
Jan 1, 2024
27.00 KRW
Jan 1, 2025
18.93 KRW
The T&L Co ROIC history
YEARROICYoY
18.93 %-29.89%
27.00 %+27.59%
21.16 %+6.41%
19.89 %-8.27%
21.68 %+55.53%
13.94 %-30.02%
19.92 %+35.11%
14.74 %-8.67%
16.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

T&L Co Stock analysis

What does T&L Co do? T&L Co., Ltd. generates revenue through the sale of medical polymer material products including wound treatment materials like hydrocolloids, foams, and hydrogels, which are essential for wound healing. The company also offers orthopedic fixing materials such as casts and splints for fracture treatment, alongside structural adhesives and water repellents. Domestic and international markets, particularly the United States, Germany, China, and Dubai, purchase these products. The firm's product portfolio targets healthcare providers and medical facilities requiring specialized materials for patient care. T&L Co., Ltd. focuses on developing medical polymer materials that serve specific clinical needs, with wound treatment materials being a key segment. Orthopedic fixing materials are sold to hospitals and clinics for fracture management, while structural adhesives and water repellents cater to industrial applications. The company's international presence in the United States, Germany, China, and Dubai supports its market diversification strategy. The firm's revenue streams are derived from the consistent demand for medical polymer products in wound care, orthopedic solutions, and industrial adhesives. Products such as hydrocolloids, foams, and hydrogels are sold to healthcare providers, while orthopedic devices like casts and splints are distributed to medical institutions. Structural adhesives and water repellents are marketed to industrial clients in key global markets. T&L Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about T&L Co stock

Return on Invested Capital (ROIC) of T&L Co is 18.93 % in 2025.

Return on Invested Capital (ROIC) of T&L Co changed from 27.00 % to 18.93 %, representing a -29.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) T&L Co since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s T&L Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — T&L Co

All Key Metrics — T&L Co